Working... Menu

The Vertos MILD™ Preliminary Patient Evaluation Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00749073
Recruitment Status : Completed
First Posted : September 9, 2008
Results First Posted : April 4, 2013
Last Update Posted : April 10, 2013
Information provided by (Responsible Party):
Vertos Medical, Inc.

Brief Summary:
This is a single-center, open label, prospective clinical study to assess the clinical application and functional outcomes of symptomatic patients undergoing the Minimally Invasive Lumbar Decompression (MILD™) treatment for lumbar spinal stenosis. In this study, patient-reported outcomes over a 3 month period following treatment will be collected by the investigator. Periodic surveys for each study subject's pain, functional status, quality of life and physical examination will track outcomes following MILD™ treatment.

Condition or disease Intervention/treatment Phase
Lumbar Spinal Stenosis Device: Minimally Invasive Lumbar Decompression (MILD™) Not Applicable

Detailed Description:
The Vertos MILD™ devices are used for image-guided Minimally Invasive Lumbar Decompression, referred to as the MILD™ procedure. This percutaneous procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. Lumbar decompression is performed through the removal of tissue and bone, where indicated. All procedures are conducted in accordance with the product labeling and indications for use. A minimum of ten up to a maximum of twenty-five adult patients will be enrolled and followed for a period of up to 6 months. Patients with symptomatic lumbar spinal stenosis who meet the study enrollment criteria will be offered the MILD™ procedure as an alternative to surgery or continued standard non-surgical medical management.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Prospective, Clinical Study to Assess the Clinical Application and Outcomes of Minimally Invasive Lumbar Decompression With the MILD™ Devices in Patients With Symptomatic Central Foraminal Lumbar Spinal Stenosis.
Study Start Date : September 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Spinal Stenosis

Arm Intervention/treatment
Percutaneous Lumbar Decompression procedure
mild percutaneous lumbar decompression procedure
Device: Minimally Invasive Lumbar Decompression (MILD™)
The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
Other Names:
  • Vertos MILD™ Devices
  • MILD™ Tool Kit
  • Vertos MILD™ Tissue Sculpter
  • Vertos Bone Sculpter Rongeur

Primary Outcome Measures :
  1. Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). [ Time Frame: Baseline and Six Months ]
    Clinical relevance established by change of two points or more on a ten point scale where zero represents no pain and ten represents worst pain imaginable. Mean change from baseline to Month 6 was reported with a positive number representing the baseline value minus the 6 month value.

  2. Function as Measured Subjectively by the Oswestry Disability Index Patient Questionnaire [ Time Frame: Baseline and Month 6 ]
    Oswestry Disability Index (ODI) is used to measure permanent functional disability through a series of questions which characterize the disturbance of activities of daily living resulting from chronic back pain. The questionnaire is divided into 10 topics including pain intensity , personal care, lifting, walking, sitting, standing, sleeping, social life, traveling and employment/homemaking. Each topic is rated 0 (no pain or no limitation) to 5 (high pain or very limited physically). The worst possible score is 50 (100% disability) and best would be zero (0% disability), thus a higher ODI score indicates greater disability.

  3. Quality of Life as Measured by the PCS Subscale of the Short-form 12 Question (SF-12) Survey. [ Time Frame: Baseline and Six months ]
    The 12-question SF-12v2 Health Survey is a validated generic measure of health status & outcomes, as opposed to one that targets a specific age, disease, or treatment group. The Physical Component Summary (PCS)takes into account the correlations among the Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), and Vitality (VT)SF-12v2 Health Survey scales to show the broad impact on PCS. Norm-based scoring is used so each scale has the same mean (50 points) and the same standard deviation (10 points) as the general US population in 1998. Scores below 50 indicate a decline in health status, with lower scores representing worse health status. Minimally Important Difference (MID) is a measure of true clinical relevance of a difference, with suggested MID for the Physical Component Summary (PCS) being 2 to 3 points. Change from baseline to 6 months is presented, where a positive value represents the 6 month value minus the baseline value.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Symptomatic lumbar spinal stenosis (LSS) primarily caused by dorsal element hypertrophy.
  2. Prior failure of conservative therapy.
  3. Radiologic evidence of LSS (L3-L5), Ligamentum flavum > 2.5 mm, confirmed by pre op MRI and/or CT.
  4. Central canal cross sectional area < 100mm2.
  5. Anterior listhesis < 2 - 3mm.
  6. Able to walk at least 10 feet unaided before being limited by pain.
  7. Available to complete 12 weeks of follow-up.
  8. A signed Informed Consent Form is obtained from the patient.
  9. Adults ≥ 18 years of age.

Exclusion Criteria:

  1. Prior surgery at intended treatment level.
  2. History of recent spinal fractures with concurrent pain symptoms.
  3. Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).
  4. Significant disk protrusion or osteophyte formation.
  5. Excessive facet hypertrophy.
  6. Bleeding disorders and/or current use of anti coagulants.
  7. Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.
  8. Epidural steroids within prior three weeks.
  9. Inability of the patient to lie prone for any reason with anesthesia support (e.g. chronic obstructive pulmonary disease (COPD), obesity, etc.).
  10. Any potential wound healing pathologies that may compromise outcomes, including: diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe COPD.
  11. Dementia and/or inability to give informed consent.
  12. Pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00749073

Layout table for location information
Canada, Saskatchewan
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8
Sponsors and Collaborators
Vertos Medical, Inc.
Layout table for investigator information
Principal Investigator: Daryl R Fourney, MD, FRCSC, FACS University of Saskatchewan, Royal University Hospital, Divison of Neurosurgery

Layout table for additonal information
Responsible Party: Vertos Medical, Inc. Identifier: NCT00749073     History of Changes
Other Study ID Numbers: C05NOV2007
First Posted: September 9, 2008    Key Record Dates
Results First Posted: April 4, 2013
Last Update Posted: April 10, 2013
Last Verified: April 2013

Keywords provided by Vertos Medical, Inc.:
Spinal Stenosis
Lumbar Spinal Stenosis
Spine Surgery

Additional relevant MeSH terms:
Layout table for MeSH terms
Constriction, Pathologic
Spinal Stenosis
Pathological Conditions, Anatomical
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases